Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP8379.RAhKG7RYfMOX-qxaOMQB26PVNSz9UhPwhxh1AVgEjnn3A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP8379.RAhKG7RYfMOX-qxaOMQB26PVNSz9UhPwhxh1AVgEjnn3A130_assertion type Assertion NP8379.RAhKG7RYfMOX-qxaOMQB26PVNSz9UhPwhxh1AVgEjnn3A130_head.
- NP8379.RAhKG7RYfMOX-qxaOMQB26PVNSz9UhPwhxh1AVgEjnn3A130_assertion description "[After adjusting for the tPA effect, the probability of good outcome (defined as modified Rankin Scale 0 to 1 or NIH Stroke Scale 0 to 1 at 3 months) at the highest three ALB doses was 81% greater than in the lower dose-tiers (relative risk [RR], 1.81; 95% confidence interval [CI], 1.11 to 2.94) and was 95% greater than in the comparable NINDS rt-PA Stroke Study cohort (RR, 1.95; 95% CI, 1.47 to 2.57).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP8379.RAhKG7RYfMOX-qxaOMQB26PVNSz9UhPwhxh1AVgEjnn3A130_provenance.
- NP8379.RAhKG7RYfMOX-qxaOMQB26PVNSz9UhPwhxh1AVgEjnn3A130_assertion evidence source_evidence_curated NP8379.RAhKG7RYfMOX-qxaOMQB26PVNSz9UhPwhxh1AVgEjnn3A130_provenance.
- NP8379.RAhKG7RYfMOX-qxaOMQB26PVNSz9UhPwhxh1AVgEjnn3A130_assertion SIO_000772 16809570 NP8379.RAhKG7RYfMOX-qxaOMQB26PVNSz9UhPwhxh1AVgEjnn3A130_provenance.
- NP8379.RAhKG7RYfMOX-qxaOMQB26PVNSz9UhPwhxh1AVgEjnn3A130_assertion wasDerivedFrom ctd_human-20130708 NP8379.RAhKG7RYfMOX-qxaOMQB26PVNSz9UhPwhxh1AVgEjnn3A130_provenance.
- NP8379.RAhKG7RYfMOX-qxaOMQB26PVNSz9UhPwhxh1AVgEjnn3A130_assertion wasGeneratedBy ECO_0000218 NP8379.RAhKG7RYfMOX-qxaOMQB26PVNSz9UhPwhxh1AVgEjnn3A130_provenance.